Get the Stockscreener App
4.66
5.28%
-0.26
After Hours:
4.62
-0.04
-0.86%
Emergent Biosolutions Inc stock is traded at $4.66, with a volume of 1.31M.
It is down -5.28% in the last 24 hours and down -33.99% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$4.92
Open:
$4.9
24h Volume:
1.31M
Relative Volume:
1.24
Market Cap:
$252.50M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.3157
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
-18.53%
1M Performance:
-33.99%
6M Performance:
-37.78%
1Y Performance:
+84.19%
1-Day Range:
$4.53
$4.94
1-Week Range:
$4.53
$5.93
52-Week Range:
$1.8201
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
4.66 | 252.50M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (NYSE:EBS) - Seeking Alpha
SEC Form DEFA14A filed by Emergent BioSolutions Inc. - Quantisnow
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts - Benzinga
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet - Simply Wall St
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - The Manila Times
Just Awarded: Emergent BioSolutions Grants Major 72,882 Share Package to Strategic New Hire - StockTitan
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues - Seeking Alpha
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - The Manila Times
Breakthrough: New High-Dose Naloxone Spray Gets Health Canada Green Light as Overdose Crisis Persists - StockTitan
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions - Medical Dialogues
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - citybiz
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc. - Equity Bulls
Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com South Africa
Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International - Marketscreener.com
Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com India
Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International - Marketscreener.com
Emergent BioSolutions Strategic Win: $36.5M Facility Sale While Securing Future Production Rights - StockTitan
Emergent BioSolutions secures $27 million in MCM orders By Investing.com - Investing.com Australia
Emergent BioSolutions secures $27 million in MCM orders - Investing.com
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - The Manila Times
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International - EIN News
Emergent BioSolutions Expands Global Reach with $27M Medical Defense Deal - StockTitan
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Emergent BioSolutions to invest in Rocketvax for vaccine developments - MSN
Emergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5M - MSN
Emergent signs financial investment agreement with Swiss Rockets - Yahoo
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - The Manila Times
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by ... - The Bakersfield Californian
First OTC Narcan Program Targets High-Risk Construction Workers to Combat Overdose Crisis - StockTitan
Emergent BioSolutions director Zoon sells $57,300 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock - Investing.com India
Emergent BioSolutions director Zoon sells $57,300 in stock - Investing.com
Emergent Bio and Rocketvax in investment deal and partnership - The Pharma Letter
Emergent BioSolutions and Rocketvax Announce Investment Agreement - Contract Pharma
Emergent Biosolutions And Rocketvax Announce Investment Agreement And Pursuit Of A Strategic Relationship For Next-Generation Product Candidates - Marketscreener.com
Emergent BioSolutions to Invest in Swiss Rockets, Rocketvax -March 12, 2025 at 08:40 am EDT - Marketscreener.com
Emergent BioSolutions, Rocketvax announce investment agreement - TipRanks
Emergent BioSolutions and Rocketvax Ltd Announce Strategic Investment and Partnership to Advance Next-Generation Vaccine Development - Nasdaq
Emergent BioSolutions and Rocketvax Announce Investment - GlobeNewswire
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewswire Inc.
Rhumbline Advisers Trims Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Syngene buys its first manufacturing facility in US for USD36.5 million - Medical Dialogues
India's Syngene International acquires first US biologics facility for $36.5 mln - Reuters
Emergent BioSolutions Sells Baltimore Facility to Syngene - TipRanks
Gaithersburg's Emergent BioSolutions to sell Baltimore plant for $36.5M - The Business Journals
Drug manufacturer to sell Baltimore plant for $36.5M - The Business Journals
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):